Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine them with other cancer therapies.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Opar, A. New class of kinase inhibitors poised to join the anticancer arsenal. Nat Rev Drug Discov 11, 819–820 (2012). https://doi.org/10.1038/nrd3880
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3880
